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Four new metal complexes {M = Pd(II) or Pt(II)} containing the ligand 9-aminoacridine (9AA) were prepared. The compounds
were characterized by FT-IR and 1H, 13C, and 195Pt NMR spectroscopies. Crystal structure of the palladium complex of formulae
[Pd(9AA)(μ-Cl)]2 · 2DMF was determined by X-ray diﬀraction. Two 9-acridine molecules in the imine form bind symmetrically
to the metal ions in a bidentate fashion through the imine nitrogen atom and the C(1) atom of the aminoacridine closing a
new ﬁve-membered ring. By reaction with phosphine or pyridine, the Cl bridges broke and compounds with general formulae
[Pd(9AA)Cl(L)] (where L = PPh3 or py) were formed. A mononuclear complex of platinum of formulae [Pt(9AA)Cl(DMSO)]
was also obtained by direct reaction of 9-aminoacridine and the complex [PtCl2(DMSO)2]. The capacity of the compounds to
modify the secondary and tertiary structures of DNA was evaluated by means of circular dichroism and electrophoretic mobility.
Both palladium and platinum compounds proved active in the modiﬁcation of both the secondary and tertiary DNA structures.
AFM images showed noticeable modiﬁcations of the morphology of the plasmid pBR322 DNA by the compounds probably due
to the intercalation of the complexes between base pairs of the DNA molecule. Finally, the palladium complex was tested for
antiproliferative activity against three diﬀerent human tumor cell lines. The results suggest that the palladium complex of formula
[Pd(9AA)(μ-Cl)]2 has signiﬁcant antiproliferative activity, although it is less active than cisplatin.
Copyright © 2007 X. Riera et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Intercalation between parallel base pairs is frequently one of
the possible modes of interaction of DNA molecule with ac-
tive drugs. Classic intercalators are plane aromatic molecules
such as acridines, phenantrolines, or phorphyrins. The fam-
ily of the aminoacridines has been extensively studied [1].
The applications in medicine of these chemical com-
pounds started in early 20th century, when derivatives of
crisaniline were found to be active against malaria, and eu-
ﬂavineandproﬂavinewereusedasantibacterialagents.These
compounds were replaced by aminacrine (9-aminoacridine)
which has similar eﬀects. Afterwards, when the aﬃnity of
the acridines for the nucleic acids and their intercalator ef-
fects were established [2, 3], the research focused on their
possible applications as anticancer agents. However, tests
conducted with simple acridines had very low activity as
antitumor drugs [4]. Systematic studies of the relationship
between the antitumor activity and several factors such as
the lipophilicity-hydrophilicity of the derivatives, their elec-
tronic and steric eﬀects have also been carried out [5]. Re-
cently, 9-aminoacridine has been assayed, in comparison
with other acridine derivatives such as pharmacotherapeu-
tic for prion disease Creutzfeldt-Jacob disease (CJD) [6]. The
incorporation of bulky groups into the acridine moiety does
not allow the intercalation of the chromophor between the
DNA base pairs and causes decreasing of the antitumor ac-
tivity [7].
In parallel, research focussed on the design of com-
pounds containing several acridine molecules joined by car-
bon chains in order to create a DNA polyintercalator ef-
fect [8–10] and on the preparation of coordination com-
pounds with one acridine group as a ligand [11, 12]w i t h
the objective of obtaining molecules capable of interaction2 Bioinorganic Chemistry and Applications
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Scheme 1: Schematic representation of the two tautomeric forms of the 9-aminoacridine.
with DNA by intercalation and by metal-base covalent bond.
Intercalation is a kinetically labile interaction and the addi-
tionalﬁxationofthemoleculetoDNAbyacovalentbondvia
the metal atom can potentially increase the activity of these
systems as antitumor agents.
The 9-aminoacridine (9AA) molecule has two symmet-
rically distributed nitrogen atoms with nucleophilic proper-
ties: the exocyclic N(9) and the endocyclic N(10), which can
coordinate to transition metal atoms. Two tautomeric forms
of the free 9-aminoacridine moiety can be adopted in solu-
tion (see Scheme 1).
Rak et al. [13–15] have described the presence of these
two forms in solution and have demonstrated that the equi-
librium composition changes when the solvent and temper-
ature change, although the authors do not conclude about
what isomer is preferentially formed.
An additional interest of this ligand resides in the fact
that the DNA interaction occurs by intercalation of 9-
aminoacridinebetweenthebasepairsofthebiomoleculeand
this is, theoritically, compatible with the preferential coordi-
nation of platinum to DNA [16–20] by the nitrogen N(7) of
the purine bases on the major groove.
Sundquist et al. [21] have described the synthesis
of coordination compounds of formulae cis-[PtCl(9AA)-
(NH3)2](NO3)a n dcis-[Pt(9AA)2(NH3)2](NO3)2 prepared
reacting a derivative of cisplatin with the ligand 9-
aminoacridine (9AA). In the two complexes, the ligand is
coordinated in its imine form, which binds to the platinum
atom in a monodentate fashion by the exocyclic nitrogen
atom. Natile and col. [22–24] have investigated the reac-
tion of 9-[(2-aminoethyl)amino]acridines with platinum(II)
substrates and also have studied the endocyclic versus exo-
cyclic N-coordination to platinum(II) and the role of metal
ions and hydrogen bond acceptors in the tautomeric equilib-
rium of nitro-derivatives of 9-aminoacridines.
More recently, the interaction of 9-aminoacridine-
carboxamide platinum complexes with DNA has been inves-
tigated, particulary their DNA sequence speciﬁcity and bind-
ing kinetics [25]. The presence of the 9-amino substituent
produces the eﬀect of shifting away from runs of consec-
utive guanines (the main binding site for cisplatin). How-
ever, an acridinecarboxamide platinum complex showed a
similar sequence speciﬁty to cisplatin. The same authors
prepared cis-dichloroplatinum(II) complexes tethered to 9-
aminoacridine-4-carboxamides and assessed their activity in
severalresistantcelllinesinvitro[26].Thesequencespeciﬁty
and kinetics of DNA adduct formation for the aforemen-
tioned compounds with HeLa cells were also compared with
those of cisplatin, resulting 4-fold faster for DNA-targeted
Pt complexes [27]. Platinum-acridine conjugates were also
prepared and tested against several tumor cell lines result-
ing active at micromolar concentrations. Mono- and bis-
acridinylthiourea platinum (II) complexes were synthesized
by Bierbach’s research group [28–30] with the aim of study-
ing DNA strands cleavage and binding modes. The inter-
action of ACRAMTU-Pt complexes {ACRAMTU = 1-[2-
(acridin-9-ylamino)ethyl]-1,3-dimethylthiourea} with DNA
have been extensively studied by Bierbach et al. [31–36]. Re-
cent results from their biophysical and biochemical stud-
ies suggest interesting binding mechanisms to the DNA
molecule.
Finally, metal derivatives of 9-aminoacridine have been
synthesized as precursors for radio iodination for potential
use in radionuclide therapy [37].
Here, the synthesis of new Pd(II) and Pt(II) complexes
of the classic intercalator 9-aminoacridine (9AA), where the
ligand acts as a (C,N)− bidentate group, is presented. The
study of their chemical, structural properties and reactivity
with DNA, as well as their antiproliferative behavior with se-
lected tumor cell lines are also described.
2. EXPERIMENTAL
2.1. Materialsandmethods
The complexes were prepared using K2[PdCl4]a n d
K2[PtCl4] from Johnson Matthey (Reading, UK); the sol-
vents used were purchased from Fluka (Madrid, Spain);
and 9-aminoacridine, Calf Thymus-DNA, and EDTA from
Sigma-Aldrich (Madrid, Spain).
ElementalanalyseswerecarriedoutonaCarloErba1500
microanalyzer at the Serveis Cient´ ıﬁco-T` ecnics of the Uni-
versity of Barcelona. Chlorine in the compounds was an-
alyzed by the Sh¨ oniger method and potentiometric titra-
tion in a titroprocessor Metrohm 636 provided with a sil-
ver combined electrode. Platinum was determined by ﬂame-
less atomic absorption spectroscopy (FAAS) using a Unicam
939 AA spectrometer with graphite furnace; the measure-
ments were done by addition and the sample was dissolved
in DMF to a concentration of 0.3mM. Palladium was mea-
sured by inductively coupled plasma-optical emission spec-
troscopy(ICP-OES)usingaThermoJarrellAshpolyscanGIE
in standard conditions at a wavelength of 340–458nm. TheX. Riera et al. 3
samples required prior mineralization to ICP after which
they were digested with concentrated nitric and perchloric
acids in pyrex tubes at 220◦C; palladium was dissolved in
100ml of Milli-Q water in acid medium [38]. The IR spectra
wererecordedinasolidstate(KBrpellets)onanFT-IRNico-
let 5DZ spectrometer in the 4000–400cm−1 range and on
an FT-IR Bomen DA-3 (CsBr pellets) for the 400–200cm−1
range. 1H{13C}, 13C{1H},a n d195Pt{1H} NMR spectra were
recorded on a Bruker DRX 250 spectrometer using CDCl3 as
solvent in the case of 1Ha n d13C spectra and DMSO-d6 in
the case of 195Pt spectrum due to the low solubility in CDCl3
of the platinum complex. Chemical shifts were measured rel-
ative to TMS in the case of 1Ha n d13C, and to K2PtCl6 in the
caseof 195PtNMRspectra.MassspectrawererunonaFisons
VG Quattro triple quadrupole analyzer in the 1800–200m/z
range using MeCN as solvent under electrospray (ESP-MS).
2.2. Synthesesofthecomplexes
[Pd(9AA)(μ-Cl)]2 ·2DMF
A solution of 0.192g (0.50mM) of cis-[PdCl2(PhCN)2][ 39]
in 10mL of CHCl3 was added to 40mL of a solution of
0.097g (0.50mM) of 9-aminoacridine in CHCl3. The mix-
ture was reﬂuxed at 60◦C for 12 hours. A brown solid was
formed after cooling. The resulting precipitate was washed
withethanolandethylicether,anddried overnightundersil-
ica gel. The solid was dissolved in a minimum amount (ca.
5mL) of a mixture of CHCl3:DMF (100:50) and the solution
was eluted in a SiO2 column (30 × 2cm) using CHCl3:DMF
(100:50) as eluent. The orange band collected from the SiO2
column was concentrated by evaporation under vacuum and
a brownish solid was obtained. Adequate crystals for X-ray
diﬀraction were obtained from a fraction collected from the
column after slow evaporation of the solvent Yield: 35%.
[Pd2C32H32N6C12O2] requires: C, 47.07; N, 10.29; H, 3.92;
found: C, 46.75; N, 10.40; H, 4.20.
[Pd(9AA)Cl(py-d5)]
This compound was obtained at NMR scale. 0.008g
(0.0098mM) of [Pd(9AA)(μ-Cl)]2 · 2DMF were dissolved in
0.7mL of DMSO-d6 and 2 drops of pyridine-d5. The solu-
tion immediately changed its color from brownish to strong
yellow.
[PdCl(9AA)(PPh3)]
In a ﬁrst step, this compound was prepared at NMR scale,
but further it was also isolated in a solid state. 0.004g
(0.0049mM) of [Pd(μ-Cl)(9AA)]2 · 2DMF were dissolved
in 0.4mL of DMSO-d6 and 0.0026g (0.0098mM) of triph-
enylphosphine dissolved in 0.3mL of DMSO-d6 were added.
The solution changed immediately from brown color to
strong yellow.
The product in solid state was prepared by the following
procedure: 0.0257g (0.0098mM) of triphenyl/phosphine,
dissolved in the minimum amount of acetone were added
t oas u s p e n s i o no f0 . 0 4g( 0 . 0 4 9m M )o f[ P d ( μ-Cl)(9AA)]2
· 2DMF in 30mL of acetone. The mixture was stirred at
roomtemperaturefor1houruntilthesoliddisappeared.The
ﬁnal yellow solution was concentrated in a rotavapor and an
oil was obtained. 20mL of diethylether were added to the oil
and a yellow precipitate was formed which was ﬁltered and
dried. Yield: 82%. [PdC31H24N2C1P] requires: C, 62.32; N,
4.69; H, 4.02; found: C, 62.80; N, 4.50; H, 4.20.
[PtCl(9AA)(DMSO)]
A suspension of 0.106g (0.25mM) of cis-[PtCl2(DMSO)2]
and 20mL of methanol was reﬂuxed until the solid dissa-
peared. A solution of 0.097g (0.50mM) of 9-aminoacridine
in the minimum amount of methanol was added and the re-
sultant mixture was reﬂuxed for 16 hour. When the solvent
was eliminated, a brownish solid remained in the bottle. The
solid was dissolved in 20mL of acetone. The solution was ﬁl-
tered on Ceolite, and ﬁnally, n-hexane was added until pre-
cipitation of a yellow solid, which was ﬁltered, washed with
small amounts of n-hexane, and dried at the air. Yield: 51%.
PtC15H15N2ClOS requires: C, 35.86; N, 5.58; H, 2.99; S, 6.37;
found: C, 36.10; N, 5,40; H, 3.10; S, 6.40.
2.3. X-raydiffraction
A [Pd(9AA)(μ-Cl)]2 · 2DMF prismatic crystal (0.1 × 0.1 ×
0.2mm) was selected and mounted on an Enraf-Nonius
CAD4 four-circle diﬀractometer. Unit-cell parameters were
determined from automatic centering of 25 reﬂections (12 <
Θ < 21◦) and reﬁned by least-squares method. Intensities
werecollectedwithgraphite monochromatized MoKα radia-
tion, using w/2Θ scan technique. 4911 reﬂections were mea-
sured in the range 2.60 > Θ > 29.97. 4715 of which were
non-equivalent by symmetry (Rint (on I) = 0.018). 3681 re-
ﬂections were assumed as observed applying the condition I
> 2σ(I). Three reﬂections were measured every two hours as
orientation and intensity control; signiﬁcant intensity decay
was not observed. Lorentz-polarization, but not absorption
corrections, was made.
The structure was solved by direct methods using
SHELXS computer program [40] for determination of
crystal structures and reﬁned by full-matrix least-squares
method with SHELX93 computer program [41] using 4665
reﬂections, (very negative intensities were not assumed). The
function minimized was Σw [(Fo)2 − (Fc)2]2, where w =
[σ2(I) + (0.0683 P)2]−1,a n dP= [(Fo)2 + 2 (Fc)2]/3; f, f
 ,a n d
f
   were taken from the international tables of X-Ray crystal-
lography [42] .A l lHa t o m sw e r ec o m p u t e da n dr e ﬁ n e dw i t h
an overall isotropic temperature factor, using a riding model.
Hydrogen coordinates as well as anisotropic thermal param-
eters are included as supplementary material.
2.4. Formationofdrug-DNAcomplexes
Stock solutions of each compound (1mg/mL) were stored in
the dark at room temperature until used. Drug-DNA com-
plex formation was accomplished by addition of CT DNA
(Calf thymus DNA) to aliquots of each of the compounds at
diﬀerent concentrations in TE buﬀer (50mM NaCl, 10mM4 Bioinorganic Chemistry and Applications
Tris-HCl, 0.1mM EDTA, pH = 7.4). The amount of com-
pound added to the DNA solution was designated as (ri)
(the input molar ratio of Pt, Pd, or 9-aminoacridine to nu-
cleotide). The mixture was incubated at 37◦C for 24 hours.
2.5. CircularDichroism
The CD spectra of the complex-DNA compounds (DNA
concentration 20mg/mL, (ri) = 0.05, 0.10, 0.30, and 0.50)
were recorded at room temperature on a JASCO J720 spec-
tropolarimeter with a 450W xenon lamp using a computer
for spectral subtraction and noise reduction. Each sample
was scanned twice in a range of wavelengths between 220–
360nm. The CD spectra drawn are the mean of three in-
dependent scans. The data are expressed as mean residue
molecular ellipticity [Θ]i nd e g r e ec m −1 · dmol−1.
2.6. DeterminationofPtandPdboundtoDNA
The drug-DNA complex solutions used for CD experiments
were kept; the DNA was afterwards precipitated twice with
2.5 volumes of cold ethanol and 0.1 volume of 3M NaAcO,
pH4.8.TheDNAwaswashedin70%ethanolandsuspended
in1mLofTEbuﬀer.TheamountofDNAineachsamplewas
measured by a double-beam Shimazdu UV-2101-PC spec-
trometer. The platinum and palladium bound to the DNA
was determined by Inductively Coupled Plasma-Mass spec-
trometer (ICP-MASS) Perkin Elmer ELAN-500. The assays
were performed in triplicate.
2.7. Electrophoreticmobilityinagarosegel
Commercial solution of pBR322 plasmid DNA, 0.25μg/μL
was used for electrophoretic mobility experiments.
4μL of charge marker were added to aliquot parts of
20μL of the adducts complex: DNA previously incubated
at 37◦C for 24 hours. The mixture was electrophoretized in
agarose gel (l% in TBE buﬀer) for 5 hours at 1.5V/cm. Af-
terwards, the DNA was dyed with thydium bromide solution
(0.5μg/mL en TBE) for 20minutes.
Samples of DNA and adduct cisplatin: DNA were used
as control. The experiment was carried out in an ECOGEN
horizontal tank connected to a PHARMACIA GPS 200/400
variable potential power supply.
2.8. Atomicforcemicroscopy(TMAFM)
pBR322 DNA was heated at 60◦ for 10 minutes to obtain
OC form. Stock solution is 1mg/mL in a buﬀer solution
of HEPES. Each sample contains 1μL of DNA pBR322 of
concentration 0.25μg/μLf o raﬁ n a lv o l u m eo f5 0 μL. The
amount of drug added was expressed as (ri), ratio between
the molar concentration of drug to number of base pairs.
Images are obtained with a Nanoscope III multimode
AFM of Digital Instruments Inc. operating in tapping mode.
2.9. Tumorcelllinesandcultureconditions
Three diﬀerent tumor cell lines were used in these experi-
ments:MCF-7breastcancercellline,DU-145prostatecancer
cell line, and HeLa cervix cancer cell line. The protocols used
in each case were the following: MCF-7 cells were routinely
maintained in DMEM medium supplemented with 10% of
fetal bovine serum (FBS), DU-145 cells in RPMI medium
supplemented with 10% of FBS and 2mmol/L of glutamine,
and HeLa cells in Ham’s F-12 medium. The cultures were
kept in an incubator at a highly humidiﬁed atmosphere of
9 5 %a i rw i t h5 %C O 2 at 37◦C.
The cells were collected from the medium and were
counted with a hemocytometer. Aliquot parts of 100μLw e r e
placed in 96 wells (2000 or 3000 cells per well for MCF-7 i
DU-145,resp.).Thecellswerepreincubatedwithoutdrugfor
48 hours (MCF-7) and for 72 hours (DU-145), at 37◦Ca n d
5% CO2 atmosphere with 95% of relative humidity. Imme-
diately before to be used, the complexes were solved in ster-
ile water or DMSO/H2O mixture at a stock concentration of
1mg/mL and ﬁltered. Aliquot parts of these solutions were
added to each well (between 20 and 50μLo fc o m p o u n dd e -
pendingontheﬁnalconcentrationrequired).Inanycase,the
concentration of DMSO in the solution in contact with the
cells was higher than 1%. After addition of the compound,
thecellswereincubatedfor48hoursintheaboveconditions.
20μL of MTT solution (5mg/mL in PBS) were added to each
well and were incubated for 3-4 hours more. Then, 150μLo f
solution of solubilization of MTT-formazan crystalls formed
(500mL DMF, 200g SDS, 20mL glacial acetic acid, 10mL
of HCl 2M and water until 1L) were added. The cellular
density was calculated in both, the control cultures and the
treated cultures, measuring the absorbance at 570nm in an
ELISA reader Labsystems Multiskan Multisoft. The IC50 val-
ues were calculated from the graphic representation of cell
survival percentage in function of drug (in μM). The data
were obtained from four independent experiments.
In the case of the HeLa cells, the methodology followed
wasbasicallyidenticalwiththefollowingdiﬀerences:number
ofcellsperwell,2000,preincubationfor24hours,incubation
for 24 hours, and concentrations of 0.1, 1, 10 i 50μM; so-
lution of solubilization of MTT-formazan crystalls, DMSO;
wavelength of reading, 490nm; reader of microplates ELISA,
ELX800G from Bio-Tek Instruments Inc.
3. RESULTS AND DISCUSSION
The main objective of this work was the synthesis, char-
acterization, and biological studies of compounds of gen-
eral formulae cis-[MCl2(9AA)2]( M= Pd ◦ Pt, 9AA = 9-
aminoacridine).
One of the most common synthetic routes of complexes
cis-[MX2(L)] or cis-[MX2(L)2] consists on the reaction of
the ligand (L) with the compounds MI
2[MCl4]( w h e r eM I =
Na or K, and M = Pd or Pt). The reaction between the 9-
aminoacridine and the compounds K2[MCl4]( M= Pd ◦ Pt)
was not successful due to their low solubility in organic sol-
vents. (i.e., methanol, ethanol, CHCl3, acetone), in which
the ligand is soluble. The use of Na2[PdCl4]y i e l d e dab r o w nX. Riera et al. 5
9AA+cis-[PdCl2(PhCN)2]
i) CHCl3
Reﬂux/12h
ii) Column
chromatography
∗
HN
N
H
Pd
Cl
2
·2DMF
L = py-d5 or PPh3
DMSO-d6
[Pd(9AA)Cl(L)]
(a)
9AA+cis-[PtCl2(DMSO)2]
MeOH
Reﬂux/16h
HN
N
H
Pt
Cl
DMSO
(b)
Scheme 2: Scheme of the synthesis of the complexes (a) [Pd(9AA)(μ-Cl)]2 and [Pt(9AA)(L)] (L = py-d5 or PPh3) and (b)
[Pt(9AA)Cl(DMSO)]: ∗De SiO2. The eluted used was a mixture CHCl3:DMF (100:50).
solid insoluble in the usual solvents which could not be com-
pletly characterized. The 1H NMR and elemental analysis re-
sults suggest that the solid is mainly a mixture of the co-
ordination compounds with 1:1 and 1:2 (metal:ligand) sto-
chiometries together with lower concentration unidentiﬁed
species.
Usingthecompoundcis-[PdCl2(PhCN)2]asstartingma-
terial in stronger reaction conditions and after puriﬁcation
of the reaction product by column chromatography, the
dimeric cyclopalladate complex bridged through chlorine
atoms of formula [Pd(9AA)(μ-Cl)]2 (see Scheme 2(a))w a s
isolated.
The cycloplatinated compound of formulae [Pt(9AA)Cl-
(DMSO)] (Scheme 2(b)), was synthesized by reaction of 9-
aminoacridineandcis-[PtCl2(DMSO)2],2:1,inmethanolre-
ﬂux. It was not possible to isolate the coordination com-
pound cis-[PtCl2(L)2] in spite of that several reaction times
(between 30 minutes and 24 hours) and temperatures (be-
tween 25 and 70◦C) were assayed. The activation of the C−H
bondisclearlyfavoredintheconditionsused.Totheauthors’
knowledge, [Pd(9AA)(μ-Cl)]2 and [Pt(9AA)Cl(DMSO)] are
the ﬁrst metallocycle derivatives of the 9-aminoacridine,
where the ligand behaves as a bidentate (C,N)− group.
Two cycloplatinated compounds derivatives of 1-nitro-9-
[{(2-alkylamino)ethyl}amino]acridine {alkyl = CH2-CH3
or CH3} were previously described by Ceci et al. [22]. In
those compounds, the ligand acts as a monoanionic terden-
tate (C,N,N )−, where the platinum atom binds simultane-
ously to two exocyclic nitrogen atoms and to the C8 car-
bon,withthefourthcoordinationsiteoccupiedbyachlorine
atom.
3.1. Reactivityofthe“Pd(µ-Cl)2 Pd”moietyin
thedinuclearcompound[Pd(9AA)(µ-Cl)]2
The reaction of the compound [Pd(9AA)(μ-Cl)]2 with
pyridine-d5 (py-d5) or with triphenylphosphine (PPh3)
yielded the corresponding monomeric compounds
[Pd(9AA)Cl(L)] (L = py-d5, PPh3) (see Scheme 2(a)).
The lability of the Pd−N bond is lower than that described
for cyclopalladated compounds of ﬁve-membered rings
derivatives of N-benzylidenaniline [43] which react with
triphenylphosphine to give [Pd(C∧N)X(L)2]a f t e rb r e a ko f
the Pd−Nb o n d( Scheme 2(a)). In spite of the addition of
excess of pyridine-d5 or PPh3, the substitution of the second
chloride ligand was not observed.
The new compounds prepared [Pd(9AA)(μ-Cl)]2·
2DMF, [Pd(9AA)Cl(L)] (L = py-d5 or PPh3)a n d
[Pt(9AA)Cl(DMSO)] were characterized by IR and 1H,
13C, 31P {in the case of [Pd(9AA)Cl(PPh3)]} and 195Pt {for
[Pt(9AA)Cl(DMSO)]} NMR spectroscopies. Molecular and6 Bioinorganic Chemistry and Applications
crystal structures for the cyclopalladated [Pd(9AA)(μ-Cl)]2·
2DMF were obtained by X-ray diﬀraction.
3.2. FT-IR
The FT-IR spectra in the range 4000–400cm−1 for the
9-aminoacridine and the complexes [Pd(9AA)(μ-Cl)]2 ·
2DMF, [Pd(9AA)Cl(PPh3)], and [Pt(9AA)Cl(DMSO)] were
recorded.
In the zone between 1670–1550cm−1 the stretching
ν(>C=N−)1 and bending δ(NH2) bands can be assigned.
The δ(NH2) band of the free ligand appears at 1670cm−1.
In the spectrum of the compound [Pd(9AA)Cl(PPh3)], the
form of the bands between 550–520cm−1, corresponding to
the triphenylphosphine molecules [44], conﬁrms the coordi-
nation of the palladium atom to only one molecule of PPh3.
In the case of the complex [Pt(9AA)Cl(DMSO)], the IR
spectrum shows an additional band at 1032cm−1 assigned
to the stretching vibration ν(>S=O) of the dimethylsulfoxide
molecule coordinated to platinum atom through the sulphur
atom [45].
3.3. 1HNMRspectra
The 1H NMR spectra assignments, corresponding to
the free ligand and the complexes [Pd(9AA)(μ-Cl)]2·
2DMF, [Pd(9AA)Cl(L)] (L = py-d5 or PPh3)a n d
[Pt(9AA)Cl(DMSO)], are collected in Table 1. All the
spectra were recorded in DMSO-d6 at room temperature
with exception of the complex [Pt(9AA)Cl(DMSO)] which
was recorded in acetone-d6. COSY and TOCSY experiments
were used for the assignment.
The spectrum of the free ligand shows four signals in the
aromatic zone, which indicates chemical equivalence of the
protons localized to both sides of the symmetry plane of the
molecule. The signals were assigned as described in the lit-
erature [46]. The spectra of the complexes are similar: they
present seven signals (between 6 and 9ppm) assigned to the
protons of the aromatic CH groups, which demonstrates the
loss of symmetry of the ligand as a consequence of the bind-
ing to the metal ion. The presence of only seven resonances
indicates the formation of a σ(Pd−Csp2, aryl) bond. On the
other side, two singlets assigned to the protons of NH groups
appear, conﬁrming the imino form for the ligand.
The value of the chemical shift of proton NH10 is δ =
11.65ppm for the palladium complexes and δ = 10.73ppm
for the platinum complex. This suggests the presence in so-
lution of a hydrogen bond between the proton bound to en-
docyclic nitrogen and the DMF molecule present in the three
palladium compounds. This type of interaction can also be
observed in solid state, in the crystal structure of compound
[Pd(9AA)(μ-Cl)]2 · 2DMF. In Figure 2 the 2D spectrum for
this complex is represented.
The spectra of the monomeric palladium compounds
[Pd(9AA)Cl(L)] (L = py-d5 or PPh3) show, as most signif-
icant feature, a strong upshift of the H2 (see Table 1). This
fact is usually observed for the proton in orto position rela-
tive to metallated carbon atom in cyclopalladate complexes
similar to those studied here [47] and it is due to the prox-
imity of this proton to the aromatic ring of pyridine-d5 or
triphenylphosphine in cis position relative to the metallated
carbon atom.
A noticeable feature in the spectrum of [Pd(9AA)-
Cl(PPh3)] (see Figure 1) is that the signal of the iminic pro-
ton (NH9) appears as a doublet due to the coupling with the
31P( 3JP-H9 = 5Hz) nucleous. For the same reason, the H2
resonance appears as a doublet of doublets (4JP-H2 = 5Hz).
The values of these coupling constants are similar to those of
analogue compounds described in the literature [48].
Inthespectrumoftheplatinumderivative(seeFigure 3),
asignalat3.49ppmassignedtotheprotonsofthetwomethyl
groups of DMSO appears. The value of the chemical shift as
well as the presence of satellites due to the coupling with the
195Pt nucleous (3JPt-H(dmso) = 21Hz) indicate that the DMSO
molecule is coordinated to the metal ion. The coupling be-
tween the platinum atom and the H2 (3JPt-H2 = 48Hz) was
also identiﬁed. On the contrary, the coupling between the
iminic proton NH9, was not observed, probably due to the
width of the signal.
3.4. NMR 13C{1H}
13C{
1H} NMR spectra of the free ligand and the com-
plexes [Pd(9AA)(μ-Cl)]2 · 2DMF, [Pd(9AA)Cl(PPh3)], and
[Pt(9AA)Cl(DMSO)] were obtained.
The signals observed in the 13C{
1H} for the ligand
were assigned as previously described in the literature [21].
The spectra of the complexes [Pd(9AA)(μ-Cl)]2 · 2DMF,
[Pd(9AA)Cl(PPh3)] and [Pt(9AA)Cl(DMSO)] show very
similar general characteristics. Bidimensional heterocorrela-
tion experiments 1H−13C were used for the assignments.
The seven crossover single peaks of the aromatic zone
in bidimensional experiments (see Figure 3), which are co-
incidental with the most intense resonances in the 13C{
1H}
NMRspectrum,conﬁrmtheformationofaσ(M−Csp2,aryl)
(M = Pd or Pt) bond.
13C{
1H} NMR spectra show as well ﬁve signals with-
out crossover peaks in herecorrelation study that were as-
signed to quaternary carbons. The less strong of these
resonances that appears downshift to the free ligand was
assigned to the metallated carbon (C1). This assignment
is conﬁrmed by the existence of 195Pt satellites in the
compound [Pt(9AA)Cl(DMSO)] and for the doublet form
due to the coupling with 31P nucleous in the complex
[Pd(9AA)Cl(PPh3)].
TheC9 signal appears in the range 171–173ppm, in good
agreement with the values described in the literature for
iminic carbons in ﬁve- or six-member ring cyclometallated
compounds derivatives of Schiﬀ bases [49].
In the 13C{
1H} NMR spectrum of [Pt(9AA)Cl(DMSO)],
the couplings with 195Pt nucleous are clearly observed. The
values for the coupling constants (Supplementary Material
available online at doi 10.1155/2007/98732.) are in good
agreement with those described in the literature [50].X. Riera et al. 7
Table 1: 1H chemical shifts (ppm) of 9-aminoacridine (9AA) and the complexes [Pd(9AA)(μ-Cl)]2 · 2DMF, [Pd(9AA)Cl(L)] (L = py-d5 or
PPh3)and[Pt(9AA)Cl(DMSO)].Thenumberingcorrespondstotheattachedschemeanditwillbethesamealongthespectroscopicstudies.
9AA [Pd(9AA)(μCl)]2
& [Pd(9AA)Cl(py-d5)]&,# [Pd(9AA)Cl(PPh3)]& [Pt(9AA)Cl(DMSO)]$
H1 8.40 d — — — —
H2 7.65 t 7.71 d 5.89 d 6.04 dd 7.95 d
H3 7.32 t 7.37 t 7.19 t 6.75 t 7.39 t
H4 7.80 d 7.14 d 7.11 d 6.88 d 7.12 d
H5 7.80 d 7.53 d 7.59 d 7.48∗ 7.62 d
H6 7.32 t 7.74 t 7.71 t 7.62∗ 7.76 t
H7 7.65 t 7.23 t 7.25 t 7.22 t 7.34 t
H8 8.40 d 8.66 d 8.60 d 8.64 d 8.66 d
NH9 — 8.94 s 8.78 w 9.08 d 8.58 w
NH10 — 11.65 s 11.68 w 11.42 s 10.73 w
s: singlet, d: doublet, t: triplet, w: wide, dd: doublet of doublets.
&DMF signals were assigned at 7.99, 2.89 and 2.30ppm.
#Pyridine-d5 signals were assigned at 7.40 and 7.80ppm.
$Recorded in acetone-d6. The spectrum shows an additional singlet at 3.49ppm assigned to the protons of the CH3 groups of DMSO
(3JPt-H(DMSO) = 21Hz).
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Figure 1: 1H NMR spectrum (zone 6–11.5ppm) of the complex [Pd(9AA)Cl(PPh3)]. ∗Signal assigned to the DMF present in the precursor
complex [Pd(9AA)(μ-Cl)]2 · 2DMF.
3.5. 31P{1H}NMRspectra
The 31P{
1H} spectrum of [Pd(9AA)Cl(PPh3)] (in DMSO-
d6) shows a singlet at 40.77ppm. The position and multi-
plicity of this signal is consistent with the data described
in the literature for the ﬁve-membered rings palladacycles
with σ(Pd−Csp2, aryl) bonds [43, 51]o fg e n e r a lf o r m u l a e
[Pd(C∧N)X(PPh3)] (X = Cl−,B r −,I − or AcO−), where the
phosphine is in trans to the iminic nitrogen.
3.6. 195PtNMRspectrum
The complex [Pt(9AA)Cl(DMSO)] has been also charac-
terized by 195Pt NMR (in acetone-d6). The spectrum con-
sists in a singlet at −3756ppm. The position of the sig-
nal [52] is similar to that described in the literature
for mono- or bis-cycloplatinated compounds of formulae
[Pt{[(η5-C5H3)CH(R)N(CH3)2]Fe(η5-C5H5)}Cl (DMSO)]
(−3763ppm for R = Ha n d−3899ppm for R = CH3)[ 50]8 Bioinorganic Chemistry and Applications
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Figure 2: 1H−13C bidimensional heterocorrelated NMR spectrum of the compound [Pd(9AA)(μ-Cl)]2 (aromatic zone) where seven peaks
of crossover are observed as indicator of the presence of a σ(M−Csp2, aryl) bond.
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Figure 3: 1H NMR spectrum of the complex [Pt(9AA)Cl(DMSO)].
Table 2: Crystal data and structure reﬁnement for [Pd(9AA)(μ-Cl)]2 · 2DMF.
Empirical formula C26H30Cl2N8Pd2
Formula weight 738.28
Crystal size (mm) 0.1 ×0.1 ×0.2
Crystal system Monoclinic
Space group P21/c
a, b, c ( ) a = 12.421(6) b = 9.538(5) c = 14.476(14)
α, β, γ (◦) α = γ = 90.0 β = 109.07(5)
Volume ( ˚ A3) 1620.9(19)
Z 1
Density (calc.) (Mg × m−3) 0.756
Absorption coeﬃcient (mm−1) 0.651
F(000) 368
Temperature (K) 293(2)
Wavelength ( ) 0.71069
θ range (◦) 2.60–29.97
Reﬂexions collected 4911
Unique reﬂexions 4715 [R(int) = 0.0182]
Data/restraints/parameters 4665/0/200
Goodness-of-ﬁt on F2 1.007
Final R R1 = 0.0336, wR1 = 0.0895
R (all data) R1 = 0.0507, wR2 = 0.0968X. Riera et al. 9
and [Pt2[{η5-C5H3CH(R)N(CH3)2}2Fe]Cl2(DMSO)2]( R=
Ho rC H 3)[ 53] where the platinum(II) is surrounded by a
CNSCl coordination environment and the ligand DMSO is
in trans position to the nitrogen atom bound to the metal
ion.
3.7. Crystalstructureof[Pd(9AA)(µ-Cl)]2 ·2DMF
The main crystallographic data and structure reﬁnement are
collected in Table 2. The molecular structure of the complex
with the numbering of the atoms is shown in Figure 4.T h e
bond distances and angles are included in Supplementary
material. The structure consists in molecules of [Pd(9AA)(μ-
Cl)]2 and DMF in a molar relationship 1:2.
In the [Pd(9AA)(μ-Cl)]2 molecules, the palladium atoms
{Pd(1) and Pd(1#)} are bound to two lligands{Cl(2) and
Cl(2#)} in cis position which act as bridges between the two
metalcentres.Thetwocoordination sitesareoccupiedbythe
exocyclicnitrogen{N(9)}andthecarbonatomC(1)fromthe
9-aminoacridine ligand, conﬁrming the proposal of the for-
mation of a σ(Pd−Csp2, aryl) bond, and the bidentate and
monoanionic ligand condition of the 9-aminoacridine.
The molecule could be viewed as the combination of
fragments “[Pd(9AA)(μ-Cl)]” sharing chlorine bridges to
form a “Pd(μ-Cl)2Pd” unit. The relative position of the met-
alated ligands is in trans, and the environment of palladium
atom is a slightly distorted square plannar.1
Thebond distancePd−N{2.023(3) ˚ A} issimilar to those
described in the literature for ﬁve-membered ring palladacy-
cles derivatives of organic ligands with >C=N− groups, such
as imines [54], oximes [55], or hydrazones [56]. The bond
length for (Pd−C) {1.987(2) ˚ A} is in good agreement with
those expected for the bonds between palladium(II) and a
Csp2, aryl (these bond distances are typically in the range
1.98 ˚ A and 2.10 ˚ A) [43, 56–60].
The bond angles involving palladium atom between
82.72(11)◦ {C(1)-Pd(1)-N(9)} and 94.31(9)◦ {Cl(2)-Pd(1)-
Cl(2#)} are in good agreement with those described in the
literature for ﬁve-membered ring cyclopalladated dinuclear
complexes [Pd(C∧N)(μ-X)]2.
Each of the two halves of the molecule has a ﬁve-
membered metallocycle formed by Pd(1), N(9), C(9), C(12),
and C(13) atoms, which is practically planar2 and forms a
3.3◦ angle with the coordination plane of the metal.
The units “Pd(μ-Cl)2Pd” are asymmetric, as indicated by
the value of the bond distances Pd(1)−Cl(2): 2.4741(13) ˚ A
and Pd(1)−Cl(2#): 2.352(2) ˚ A. This result is consistent with
the structural data obtained for dimeric cyclopalladated
1 The equation of the plane deﬁned by the atoms Cl(2), Cl(2#), N(9), and
C(1) is (−0.1236)XO + (0.9015)YO + (0.4146)ZO = 4.2986. The devi-
ations related to the main plane are Cl(2): −0.035, Cl(2#): 0.037, N(9):
0.045, and C(1): −0.047 ˚ A.
2 The equation of the plane deﬁned by the atoms Pd(1), N(9), C(9), C(1),
and C(13) is (−0.1700)XO + (0.9087)YO + (0.3808)ZO = 4.2078. The de-
viations related to the main plane are Pd(1): −0.019, N(9): −0.023, C(9):
0.015, C(1): −0.019, and C(13): 0.008 ˚ A.
complexes with chlorine bridges and trans conﬁguration of
the two palladate groups of general formula [Pd(C∧N)(μ-
Cl)]2. This is a consequence of the diﬀerent inﬂuence of the
atoms in trans position {the metallated carbon (C1) and the
nitrogen N(9)} [43].
The planar unit “Pd(μ-Cl)2Pd”3 forms a 4.9◦ angle
with the metallocycle (see Figure 5) and it has a rhom-
boidalshape.Thedistancebetweenthetwopalladiumatoms,
3.479(1) ˚ A,istoolargetoconsidertheexistenceofsigniﬁcant
Pd ··· Pd interactions.
The bond angle Cl(2)−Pd(1)−Cl(2#) is similar to
those described for compounds of general formula trans-
[Pd(C∧N)(μ-Cl)]2 containing ﬁve-membered metallocycles
[61].
The tricyclic system [6,6,6] of the aromatic ligand is
practically planar4 and it forms a 2.4◦ angle with the pal-
ladacycle. This is in contrast with what occurs in other re-
ported structures [22] where the 9-aminoacridine is bound
to the metal through its exocyclic nitrogen is also present
as imino tautomer and a folding of the side rings with
respect to the N(10)−C(9) vector was found. One of the
most signiﬁcant structural features of the 9-aminoacridine
groupinthecompound[Pd(9AA)(μ-Cl)]2 isthebondlength
N(9)−C(9),1.312(3) ˚ A,whichisappreciablysmallerthanthe
expected value for a σ(Csp2−Nsp3) bond and very similar
to those described in the literature for complexes contain-
ing the functional group >C=N− (see footnote 1) and also
for the platinum compound [Pt(L)Cl], where L = 1-nitro-
9-[{2-(dimethylamino)ethyl}amino]acridine [22] with the
presence of the tautomeric form imino.
Moreover, the bond distances N(10)−C(11)
{1.399(4) ˚ A} and N(10)−C(14) {1.379(3) ˚ A} and the
bond angle C(11)−N(10)−C(14) {122.3(2)◦} in the
complex [Pd(9AA)(μ-Cl)]2 are higher than expected for
an amino form and very similar to those found for the
cited platinum complex [22]. These observations allow
to conclude that in the complex [Pd(9AA)(μ-Cl)]2 the
ligand is present in the imino form and that the func-
tional group >C=N− is included in the ﬁve-membered
metallocycle.
The bond distances and angles found for the two
moleculesofdimethylformamidepresentinthecrystalstruc-
ture of [Pd(9AA)(μ-Cl)]2 · 2DMF are similar to those de-
scribed in the literature for complexes containing DMF crys-
tallization molecules. The distance between the oxygen atom
of DMF and the hydrogen bound to the endocyclic nitrogen,
N(10),ofthecomplex[Pd(9AA)(μ-Cl)]2 {O ···H−N(10)=
2.857(4) ˚ A} suggests the existence of intermolecular hydro-
gen interactions. The strong downﬁeld shift observed in the
proton NMR spectrum assigned to the H10 (δ = 11.65ppm),
could conﬁrm the existence of these interactions in solution.
3 The equation of the plane deﬁned by the four atoms involved in the unit
“Pd(μ-Cl)2P d ”i s( −0.1050)XO + (0.8943)YO + (0.4350)ZO = 4.2649.
4 The equation of the plane deﬁned by the 14 atoms involved in the tri-
cycle system of the acridine molecule is (−0.2109)XO + (0.9051)YO +
(0.3693)ZO = 4.0107.10 Bioinorganic Chemistry and Applications
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Figure 4: Molecular structure of the complex [Pd(9AA)(μ-Cl)]2 · 2DMF.
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Figure5:Geometryofthefragment“Pd(μ-X)2Pd”anddependence
of the distance Pd ··· Pd with the angle Φ.
4. BIOLOGICAL STUDIES
4.1. CircularDichroism
The molecules of 9-aminoacridine (9AA) and complexes
[Pd(9AA)(μ-Cl)]2 and [Pt(9AA)Cl(DMSO)] originate mod-
iﬁcations in the spectrum of Calf Thymus DNA at diﬀerent
values of (ri)s e l e c t e da si ti ss h o w ni nFigure 6. The wave-
lengths, corresponding to the maximum and minimum val-
ues of the ellipticity, are collected in Table 3.
The complexes [Pd(9AA)(μ-Cl)]2 and [Pt(9AA)Cl-
(DMSO)]caninteractwiththeDNA,inprinciple,byinterca-
lation of the ligand and/or forming a covalent bond through
the metal ion.
Looking at the spectrum recorded for the CT-DNA incu-
bated with the complex [Pd(9AA)(μ-Cl)]2 (see Figure 6(b)),
a very strong decreasing of the ellipticity of both, the posi-
tive and negative bands, and a batochromic shift of the bands
can be observed. This is the opposite eﬀect to that observed
for the free 9-aminoacridine (9AA) (see Figure 6(a)). In the
case of the platinum compound [Pt(9AA)Cl(DMSO)] (see
Figure 6(c)),thechangeinthenegativebandissimilartothat
of the palladium compound but the maximum is much less
intense.
Ontheotherhand,theamountsofmetalincorporatedto
the DNA are much higher for the palladium compound than
for the platinum compound (see Table 3). Moreover, the
complex[Pd(9AA)(μ-Cl)]2 givesapercentageofmetalincor-
poration higher than cisplatin at the molar relationships (ri)
used.ThesmallpercentageofplatinumincorporatedtoDNA
for [Pt(9AA)Cl(DMSO)] may be conditioned by the diﬀer-
ent labilization kinetic of 9-aminoacridine and chlorine ions
and/or the fact that the compound [Pt(9AA)Cl(DMSO)]
contains only a hydrolysable chlorine and the most probable
adductthatcouldbeformedwithDNAwouldbemonofunc-
tional.
In conclusion, the 9-aminoacridine behaves as a classi-
cal intercalator but the palladium and platinum complexes
produce changes of diﬀerent nature, probably due to the for-
mation of a covalent bond or the occurrence of both interac-
tions, covalent, and intercalation, simultaneously.
4.2. Electrophoreticmobility
In Figure 7, the electrophoretic mobility pattern of cis-
platin, 9-aminoacridine and the complex [Pd(9AA)(μ-Cl)]2
are shown. At low values of (ri), a decreasing of the CCC
form mobility for the free 9-aminoacridine molecule (lane
C) can be observed. However, at (ri) = 0.5, the mobility in-
creases. This behavior is similar to that observed for cis-
platin at higher concentrations than the ones used in this
study. The intercalation interaction usually causes a higher
degree of supercoiling than the one produced by a covalent
cis-bifunctional binding [62].
On the other hand, the electrophoretic behavior of
pBR322, incubated with the compound [Pd(9AA)(μ-Cl)]2
(Figure 7, lane B), is close to that of cisplatin (Figure 7,l a n e
A) which seems to indicate that the interaction of this com-
pound is not only intercalative. This seems to agree with the
results obtained from the circular dicroism study described
in the previous section.
Finally,thecomplex[Pt(9AA)Cl(DMSO)](Figure 8,lane
B) causes slight modiﬁcations in the electrophoretic mobil-
ity of the OC while the CCC form retards, which suggests
that the uncoiling of the helix occurs on a minor degree.
It is possible that, in addition to the intercalation, a mono-
functional covalent binding could be established. This re-
sult would agree with the published results for the complex
[PtCl(dien)]Cl, which uncoils the helix about 6◦,h a l fo ft h e
value expected for a cis bifunctional binding as int the values
described for cisplatin [62].
4.3. Atomicforcemicroscopy
AFMimagesoftheplasmidpBR322DNAincubatedwiththe
compounds [Pd(9AA)(μ-Cl)]2 and [Pd(9AA)Cl(PPh3)] forX. Riera et al. 11
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Figure 6:DCspectraofCalfThymusDNAincubatedwith(a)9-aminoacridine(9AA),(b)[Pd(9AA)(μ-Cl)]2,and(c)[Pt(9AA)Cl(DMSO)].
Table 3: Ellipticity values and wavelenghts (maximum and minimum) in CD spectra of Calf Thymus DNA incubated with 9-aminoacridine
(9AA) and its palladium and platinum complexes.
Compound ri θmax
(a) λmax
(b) θmin
(a) λmin
(b) %u p t a k e nm e t a l
DNA(c) — 9.0 275.0 −9.5 245.5 —
9AA 0.01 9.8 274.1 −10.9 246.0 —
0.10 15.3 270.0 −15.9 247.0 —
0.25 22.7 269.2 −22.1 247.0 —
0.50 30.0 268.8 −26.5 247.8 —
[Pd(9AA)(μ-Cl)]2 0.01 8.8 274.5 −10.1 245.8 62.24
0.10 7.8 274.4 −9.8 244.8 51.82
0.25 5.7 277.6 −7.4 247.0 50.48
0.50 2.4 282.4 −3.7 250.0 52.67
DNA(d) — 6.6 276.0 −7.9 245.0 —
[Pt(9AA)Cl(DMSO)] 0.01 6.6 276.0 −8.1 245.6 9.72
0.10 6.7 272.8 −7.7 245.8 7.43
0.25 6.7 272.5 −6.0 246.5 6.21
0.50 6.2 273.8 −3.2 247.1 5.44
(a)degrees × cm2 × dmol−1 × 103;
(b)nm;
(c)6.49 × 10−5 mol × l−1;
(d)6.10 × 10−5 mol × l−1.12 Bioinorganic Chemistry and Applications
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Figure 7: Eletrophoretic mobility pattern of pBR322 plasmid
DNA incubated with the complexes: lane A: cisplatin; lane B:
[Pd(9AA)(μ-Cl)]2; lane C: 9AA.
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Figure 8: Electrophoretic mobility pattern of pBR322 plasmid
DNA incubated with the complexes: lane A: cisplatin; lane B:
[Pt(9AA)Cl(DMSO)].
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Figure 9: AFM image of the pBR322 plasmid DNA incubated with
the complex [Pd(9AA)(μ-Cl)]2.
5h o u r sa n d3 7 ◦Ca r ep r e s e n t e di nF i g u r e s9 and 10,r e s p e c -
tively.
In all the images supercoiled forms of the plasmid
DNA can be observed. These modiﬁcations are likely to
correspond to the strong eﬀect of intercalation of the 9-
aminoacridine ligand.
Supercoiling in the plasmid DNA tertiary structure has
been observed before for other classic intercalators such as
ethydium bromide and planar heterocycles [63, 64].
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Figure 10: Two AFM images corresponding to pBR322 plasmid
DNA incubated with the complex [Pd(9AA)Cl(PPh3)].
In the case of the complex [Pd(9AA)Cl(PPh3)], addi-
tional interaction, probably due to the formation of covalent
bond with the N atom of the purine bases, originates deeper
changes in the structure of the plasmid.
4.4. Antiproliferativeassays
The “in vitro” growth inhibitory eﬀect of the 9-amino-
acridine and its palladium complex [Pd(9AA)(μ-Cl)]2 were
evaluated in three tumor cell lines: MCF-7 breast cancer cell
line, DU-145 prostate cancer cell line, and HeLa cervix can-
cer cell line.
In Table 4,theIC50 valuesforthetwocompoundsagainst
the three tumor cell lines are collected. The 9-aminoacridine
again presents low IC50 values against the tumor cell linesX. Riera et al. 13
Table 4: IC50 values (μM) for the compounds studied against the
tumor cell lines MCF-7, DU-145, and HeLa.
Compound MCF-7 DU-145 HeLa
cisplatin 9.4 3.7 22.2
9AA 4.9 11.9 22.2
[Pd(9AA)(μ-Cl)]2 38.1 32.6 > 50
assayed. These results suggest a direct correlation with the
conclusions drawn from the studies of interaction with DNA
in previous sections. Many other compounds related to
acridines have demonstrated intercalation in DNA and an-
tiproliferativebehavior[65].Althoughthe[Pd(9AA)(μ-Cl)]2
derivative shows higher IC50 values than cisplatin, the pa-
rameters are low enough to merit consideration in further
biochemical studies.
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